Medivir AB (OSTO:MVIR) Cyclically Adjusted Book per Share: kr9.65 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MVIR Medivir AB OSTO:MVIR
53 GF Score
Price kr1.70
GF Value kr1.22
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Medivir AB Cyclically Adjusted Book per Share?

Medivir AB OSTO:MVIR -3.19% 53 Cyclically Adjusted Book per Share is kr9.65 as of Jun. 2026. GuruFocus rates OSTO:MVIR with a GF Score™ of 53/100 and a GF Value™ of kr1.22 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Medivir AB's adjusted book value per share for the three months ended in Jun. 2026 was kr0.479. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr9.65 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Medivir AB's average Cyclically Adjusted Book Growth Rate was -32.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -18.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Medivir AB was 0.10% per year. The lowest was -18.90% per year. And the median was -3.10% per year.

As of today (2026-09-18), Medivir AB's current stock price is kr1.70. Medivir AB's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was kr9.65. Medivir AB's Cyclically Adjusted PB Ratio of today is 0.18.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Medivir AB was 2.89. The lowest was 0.03. And the median was 0.31.


Medivir AB  (OSTO:MVIR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Medivir AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.70/9.649
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Medivir AB was 2.89. The lowest was 0.03. And the median was 0.31.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Medivir AB Cyclically Adjusted Book per Share Related Terms


Medivir AB Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Medivir AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medivir AB Cyclically Adjusted Book per Share Chart

Medivir AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.91 22.53 21.32 15.93 11.18

Medivir AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.31 13.05 11.84 10.69 9.65

OSTO:MVIR vs VRTX, REGN, MRNA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Medivir AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Medivir AB's Cyclically Adjusted PB Ratio falls into.


OSTO:MVIR
53GF Score
Medivir AB OSTO:MVIR
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medivir AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medivir AB's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.479/134.6100*134.6100
=0.479

Current CPI (Jun. 2026) = 134.6100.

Medivir AB Quarterly Data

Book Value per Share CPI Adj_Book
201609 32.957 101.138 43.864
201612 43.309 102.022 57.143
201703 26.189 102.022 34.554
201706 23.145 102.752 30.321
201709 20.442 103.279 26.643
201712 17.030 103.793 22.086
201803 16.239 103.962 21.026
201806 13.677 104.875 17.555
201809 11.697 105.679 14.899
201812 8.524 105.912 10.834
201903 6.975 105.886 8.867
201906 6.637 106.742 8.370
201909 5.999 107.214 7.532
201912 5.113 107.766 6.387
202003 4.467 106.563 5.643
202006 4.109 107.498 5.145
202009 4.240 107.635 5.303
202012 3.932 108.296 4.887
202103 4.925 108.360 6.118
202106 4.671 108.928 5.772
202109 4.483 110.338 5.469
202112 4.133 112.486 4.946
202203 3.652 114.825 4.281
202206 3.312 118.384 3.766
202209 3.095 122.296 3.407
202212 2.834 126.365 3.019
202303 2.556 127.042 2.708
202306 2.137 129.407 2.223
202309 1.799 130.224 1.860
202312 2.086 131.912 2.129
202403 1.873 132.205 1.907
202406 1.536 132.716 1.558
202409 1.264 132.304 1.286
202412 1.030 132.987 1.043
202503 0.915 132.825 0.927
202506 0.710 133.699 0.715
202509 0.583 133.480 0.588
202512 0.346 133.380 0.349
202603 0.355 133.550 0.358
202606 0.479 134.610 0.479

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of kr9.65 mean?
Medivir AB (OSTO:MVIR) has a Cyclically Adjusted Book per Share of kr9.65 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Medivir AB and its competitors.
Is Medivir AB's Cyclically Adjusted Book per Share too high?
Medivir AB's current Cyclically Adjusted Book per Share is kr9.65. Overall, Medivir AB has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Medivir AB's Cyclically Adjusted Book per Share of kr9.65 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Medivir AB and its competitors. Medivir AB's current Cyclically Adjusted Book per Share is kr9.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (OSTO:MVIR) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.22, compared to a current price of kr1.70 — trading 39.3% above its estimated fair value. The current Cyclically Adjusted Book per Share is kr9.65. Medivir AB's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Medivir AB (OSTO:MVIR), the current Cyclically Adjusted Book per Share is kr9.65 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medivir AB (OSTO:MVIR) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of kr1.70 is trading 39.3% above its estimated GF Value™ of kr1.22. GuruFocus considers Medivir AB to be Significantly Overvalued.

Key valuation signals for OSTO:MVIR:

  • Cyclically Adjusted Book per Share: kr9.65
  • GF Value™: kr1.22 vs. price of kr1.70 (39.3% above fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the OSTO:MVIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medivir AB Business Description

Other Exchanges MVIRs:UK0GP7:UKMVR0:Germany
Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
53GF Score

Get the complete analysis for OSTO:MVIR

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.70
Price
kr1.22
GF Value